FSRH CEU Statement: Mirena® 52mg LNG-IUD extension of licence for contraception to 8 years

Posted 11 January 2024

Date: 11 Jan 2024

Type: FSRH Clinical Guidance and Clinical Statements

The Mirena® 52mg LNG-IUD has now been licensed for 8 years for contraception.

The United Kingdom Medicines Health Regulatory Authority (MHRA) has approved an extension to the Mirena licence from 5 years to 8 years for contraception. This supersedes the current advice in the Intrauterine Contraception Guideline. There has not been an extension to the licensed duration of use when being used for the management of heavy menstrual bleeding, or for endometrial protection as part of hormone replacement therapy (HRT). 
 
The full statement is available below to view and download